<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04361331</url>
  </required_header>
  <id_info>
    <org_study_id>zs-ICC-2020</org_study_id>
    <nct_id>NCT04361331</nct_id>
  </id_info>
  <brief_title>Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic Cholangiocarcinoma</brief_title>
  <official_title>A Randomized, Open, Two-cohort Phase 2 Study of Toripalimab(PD1) Combined With Lenvatnib, or Gemox Chemotherapy Combined With Lenvatinib as First-line Therapy in Patients With Advanced or Unresectable Intrahepatic Cholangiocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We aim to explore the effects and safety of the two cohorts of toripalimab combined with
      lenvatinib or gemox combined with lenvatinib as first-line therapy in advanced or
      unresectable intrahepatic cholangiocarcinoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For advanced intrahepatic cholangiocarcinoma (ICC) that cannot be surgically removed or
      accompanied by metastasis, the NCCN guidelines (NCCN guidelines hepatobiliary cancer, 2019)
      recommend that the current treatment options are limited, mainly recommending gemcitabine
      combined with platinum-based antitumor drugs (cisplatin, oxaliplatin, etc.) chemotherapy as
      first-line treatment. Adding targeted drugs can enhance the anti-tumor effect. For those with
      microsatellite instability, it is recommended to add anti-PD1(programmed cell death protein
      1) antibody. Gemox chemotherapy (oxaliplatin + gemcitabine) has been used in the treatment of
      advanced intrahepatic cholangiocarcinoma, but the efficacy is still not satisfactory.
      Lenvatinib is a small-molecule multi-kinase inhibitor that is currently approved for
      first-line treatment of advanced hepatocellular carcinoma. In recent years, the anti-PD1
      antibody has shown efficacy in the treatment of primary liver cancer. Lenvatinib combined
      with anti-PD1 antibody or chemotherapy may have a better effect than single use for advanced
      ICC. At present, lenvatinib combined with anti-PD1 antibody or lenvatinib combined with Gemox
      in the first-line treatment of advanced ICC has not been reported.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 6, 2020</start_date>
  <completion_date type="Anticipated">December 6, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 6, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Arm1: toripalimab combined with lenvatinib， Arm 2: lenvatinib combined with Gemox</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Random number table grouping</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>12 months</time_frame>
    <description>Objective response rate of advanced and unresectable intrahepatic cholangiocarcinoma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: the potential side effects</measure>
    <time_frame>12 months</time_frame>
    <description>The potential side effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>12 months</time_frame>
    <description>From the beginning date of combined therapy to the date of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>12 months</time_frame>
    <description>From the beginning date of combined therapy to disease progression or death, whichever occurs first.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cholangiocarcinoma, Intrahepatic</condition>
  <arm_group>
    <arm_group_label>Toripalimab combined with lenvatinib</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Toripalimab: 240 mg, intravenous infusion, Q3W;
Lenvatinib: 8mg (body weight &lt;60kg) or 12mg (body weight ≥60kg), qd;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lenvatinib combined with gemox</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Lenvatinib: 8mg (body weight &lt;60kg) or 12mg (body weight ≥60kg), qd
Gemox chemotherapy D1: Oxaliplatin 85mg / m2, Gemcitabine 1g / m2 D8: Gemcitabine 1g / m2 Three weeks are a course, a total of 6-8 courses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvatinib combined with gemox</intervention_name>
    <description>Arm2: Lenvatinib + gemox</description>
    <arm_group_label>Lenvatinib combined with gemox</arm_group_label>
    <other_name>gemox chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Toripalimab combined with lenvatinib</intervention_name>
    <description>Toripalimab combined with lenvatinib</description>
    <arm_group_label>Toripalimab combined with lenvatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. The patient must be required to sign an informed consent; 2. Age 18-75 years old,
             male or female; 3. ECOG performance status score (PS score) 0 or 1 point; 4.
             Child-Pugh score A; 5. Intrahepatic cholangiocarcinoma confirmed by histopathology;
             agree to provide previously stored tumor tissue samples or fresh biopsy tumor lesions;
             6. Unresectable ICC patients or postoperative ICC recurrence and metastasis, without
             systematic treatment within 6 months; 7. The functional indicators of vital organs
             meet the following requirements

               1. Neutrophils ≥1.5 * 109 / L; platelets ≥100 * 109 / L; hemoglobin ≥9g / dl; serum
                  albumin ≥3g/dl;

               2. Thyroid stimulating hormone (TSH) ≤ 1 times the upper limit of normal value(ULN),
                  T3 and T4 are in the normal range;

               3. Bilirubin ≤ 1.5 times ULN; ALT and AST ≤ 3 times ULN;

               4. Serum creatinine ≤ 1.5 times ULN, creatinine clearance rate ≥ 60ml/min
                  (calculated using Cockcroft-Gault formula); 8. Subject has at least 1 measurable
                  lesion (according to RECIST1.1); 9. Non-lactating or pregnant women,
                  contraception during or 3 months after treatment.

        Exclusion Criteria:

          -  1. Pathological diagnosis of hepatocellular carcinoma, mixed hepatocellular carcinoma
             and other non-cholangiocarcinoma malignancies; 2. Existing or concurrently suffering
             from other malignant tumors, except for fully treated non-melanoma skin cancer,
             cervical carcinoma in situ, and papillary thyroid cancer; 3. Have used lenvatinib or
             gemcitabine-based chemotherapy within 6 months or have used PD1 monoclonal antibody
             and PD-L1 monoclonal antibody treatment; 4. Severe cardiopulmonary and renal
             dysfunction; 5. Hypertension that is difficult to control by the drug (systolic blood
             pressure (BP) ≥140 mmHg and / or diastolic blood pressure ≥90 mmHg) (based on the
             average of ≥3 BP readings obtained from ≥2 measurements); 6. Abnormal blood
             coagulation function (PT&gt; 14s), have bleeding tendency or are receiving thrombolysis
             or anticoagulation treatment; 7. HBV DNA&gt; 2000 copies/ml and HCV RNA&gt;1000 after
             antiviral treatment; 8. Have a history of esophagogastric varices, with significant
             clinically significant bleeding symptoms or a clear tendency to appear within 3 months
             before enrollment; 9. Active infection requiring systemic treatment and treatment;
             patients with active tuberculosis infection within 1 year before enrollment; a history
             of active tuberculosis infection more than 1 year before enrollment, have not received
             regular anti-TB treatment or tuberculosis Still in the active period; 10. Human
             immunodeficiency virus (HIV, HIV1/2 antibody) positive; 11. Have a history of
             psychotropic substance abuse, alcohol or drug abuse; 12. Known to have a history of
             severe allergies to any monoclonal antibodies, anti-angiogenic targeted drugs, and
             platinum or gemcitabine; 13. Other factors that may affect the safety of subjects or
             test compliance as judged by the investigator. Such as serious illness (including
             mental illness) requiring combined treatment, severe laboratory abnormalities, or
             other family or social factors.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jian Zhou, MD &amp; PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Zhongshan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiao-yong Huang, MD</last_name>
    <phone>+8615021519215</phone>
    <email>huang.xiaoyong@zs-hospital.sh.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Guo-ming Shi, MD</last_name>
    <phone>+8613916969578</phone>
    <email>shi.guoming@zs-hospital.sh.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Huang xiaoyong</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiao-yong Huang, MD</last_name>
      <phone>+8615021519215</phone>
      <email>huang.xiaoyong@zs-hospital.sh.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongshan hospital</name>
      <address>
        <city>Shanghai</city>
        <state>上海</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>xiaoyong Huang, MD</last_name>
      <phone>+8615021519215</phone>
      <email>huang.xiaoyong@zs-hospital.sh.cn</email>
    </contact>
    <investigator>
      <last_name>Jian Zhou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>André T, Tournigand C, Rosmorduc O, Provent S, Maindrault-Goebel F, Avenin D, Selle F, Paye F, Hannoun L, Houry S, Gayet B, Lotz JP, de Gramont A, Louvet C; GERCOR Group. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol. 2004 Sep;15(9):1339-43.</citation>
    <PMID>15319238</PMID>
  </results_reference>
  <results_reference>
    <citation>Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1.</citation>
    <PMID>29433850</PMID>
  </results_reference>
  <results_reference>
    <citation>El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH Rd, Meyer T, Kang YK, Yeo W, Chopra A, Anderson J, Dela Cruz C, Lang L, Neely J, Tang H, Dastani HB, Melero I. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017 Jun 24;389(10088):2492-2502. doi: 10.1016/S0140-6736(17)31046-2. Epub 2017 Apr 20.</citation>
    <PMID>28434648</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, Sarker D, Verset G, Chan SL, Knox J, Daniele B, Webber AL, Ebbinghaus SW, Ma J, Siegel AB, Cheng AL, Kudo M; KEYNOTE-224 investigators. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018 Jul;19(7):940-952. doi: 10.1016/S1470-2045(18)30351-6. Epub 2018 Jun 3. Erratum in: Lancet Oncol. 2018 Sep;19(9):e440.</citation>
    <PMID>29875066</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 22, 2020</study_first_submitted>
  <study_first_submitted_qc>April 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>April 23, 2020</last_update_submitted>
  <last_update_submitted_qc>April 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>intrahepatic Cholangiocarcinoma</keyword>
  <keyword>Lenvatinib</keyword>
  <keyword>Gemox chemotherapy</keyword>
  <keyword>Programmed cell death protein 1 antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

